Serina Therapeutics Announces Issuance of Key Patents in China and Europe Extending the POZ Patent Estate Globally

Huntsville, AL, March 6th, 2014

Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology for drug development, announced today that the company has received notice from the European Patent Office and the Peoples Republic of China that key patents in the pendant polyoxazoline (POZ) family of patents have been granted issuance.

“This platform of POZ patents is unique in composition, methods and utility,” according to Dr. Tacey Viegas, Chief Operating Officer of Serina Therapeutics, Inc. “The issuance of key patents in our family of pendent POZ patents in territories outside of the USA continues to strengthen our patent estate and build international acceptance. We now have over twenty patent applications pending worldwide.”

Serina’s issued patents can be viewed on the Publications and Patents page of the Serina website.

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled twelve approved polyethylene glycol (PEG) products for various pharmaceutical partners. Besides developing its own pipeline of pharmaceutical products for Parkinson’s disease and cancer, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.

For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com